Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT OTCMKTS:EMIS NASDAQ:VERU NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AEMISEmisphere Technologies$9.90-0.4%$7.94$9.90▼$9.95N/AN/A424,381 shs7,262 shsVERUVeru$3.80+2.2%$3.71$2.64▼$14.20$54.53M-0.75148,646 shs110,127 shsXENEXenon Pharmaceuticals$40.76-1.1%$38.91$26.74▼$46.00$3.18B1.14811,494 shs858,981 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%EMISEmisphere Technologies-0.40%+26.76%+26.76%+26.76%+26.76%VERUVeru+2.15%-7.54%+10.14%-32.24%-56.55%XENEXenon Pharmaceuticals-1.07%-2.09%+11.40%+34.52%-2.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AEMISEmisphere Technologies$9.90-0.4%$7.94$9.90▼$9.95N/AN/A424,381 shs7,262 shsVERUVeru$3.80+2.2%$3.71$2.64▼$14.20$54.53M-0.75148,646 shs110,127 shsXENEXenon Pharmaceuticals$40.76-1.1%$38.91$26.74▼$46.00$3.18B1.14811,494 shs858,981 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%0.00%EMISEmisphere Technologies-0.40%+26.76%+26.76%+26.76%+26.76%VERUVeru+2.15%-7.54%+10.14%-32.24%-56.55%XENEXenon Pharmaceuticals-1.07%-2.09%+11.40%+34.52%-2.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AEMISEmisphere Technologies 0.00N/AN/AN/AVERUVeru 2.50Moderate Buy$33.33777.19% UpsideXENEXenon Pharmaceuticals 2.92Moderate Buy$53.6731.67% UpsideCurrent Analyst Ratings BreakdownLatest CALT, EMIS, XENE, and VERU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025VERUVeruWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025XENEXenon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VERUVeruWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025XENEXenon PharmaceuticalsBloom BurtonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/7/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.009/27/2025VERUVeruWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XENEXenon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.008/13/2025VERUVeruRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $20.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AVERUVeru$16.89M3.30N/AN/A$2.21 per share1.72XENEXenon Pharmaceuticals$9.43M333.30N/AN/A$9.90 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AVERUVeru-$37.80M-$2.20N/AN/AN/AN/A-143.24%-85.22%12/15/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest CALT, EMIS, XENE, and VERU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025XENEXenon Pharmaceuticals-$1.16N/AN/AN/AN/AN/A8/12/2025Q3 2025VERUVeru-$0.55-$0.50+$0.05-$0.50N/AN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59EMISEmisphere TechnologiesN/AN/AN/AVERUVeruN/A2.422.42XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%EMISEmisphere TechnologiesN/AVERUVeru47.16%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%EMISEmisphere Technologies72.90%VERUVeru15.20%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableVERUVeru23014.66 million12.43 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableCALT, EMIS, XENE, and VERU HeadlinesRecent News About These CompaniesStifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)October 23 at 7:31 AM | theglobeandmail.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 18, 2025 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 18, 2025 | marketbeat.comXenon Pharmaceuticals appoints Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | msn.comXenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization EffortsOctober 16, 2025 | tipranks.comXenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of AzetukalnerOctober 16, 2025 | quiverquant.comQXenon Announces Appointment of Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | globenewswire.comXenon (XENE) Receives a Buy from JefferiesOctober 16, 2025 | theglobeandmail.comXenon Pharmaceuticals (NASDAQ:XENE) Earns "Sell (D-)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comInvestors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)October 16, 2025 | marketbeat.comAberdeen Group plc Boosts Position in Xenon Pharmaceuticals Inc. $XENEOctober 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Sell (D-)" Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comXenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price MomentumOctober 12, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for XENE FY2025 EarningsOctober 10, 2025 | marketbeat.comBrokers Offer Predictions for XENE FY2026 EarningsOctober 8, 2025 | marketbeat.comBloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy"October 8, 2025 | marketbeat.comChardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy RecommendationOctober 7, 2025 | msn.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | globenewswire.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William BlairOctober 7, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan CapitalOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCALT, EMIS, XENE, and VERU Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 10/23/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Emisphere Technologies OTCMKTS:EMIS$9.90 -0.04 (-0.40%) As of 10/24/2025 03:59 PM EasternEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Veru NASDAQ:VERU$3.80 +0.08 (+2.15%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.82 +0.02 (+0.53%) As of 10/24/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Xenon Pharmaceuticals NASDAQ:XENE$40.76 -0.44 (-1.07%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$40.76 0.00 (0.00%) As of 10/24/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
